COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
[HTML][HTML] Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies
Lectins or clusters of carbohydrate-binding proteins of non-immune origin are distributed
chiefly in the Plantae. Lectins have potent anti-infectivity properties for several RNA viruses …
chiefly in the Plantae. Lectins have potent anti-infectivity properties for several RNA viruses …
DoE-derived continuous and robust process for manufacturing of pharmaceutical-grade wide-range LNPs for RNA-vaccine/drug delivery
Lipid nanoparticle (LNP) technology has become extremely demanding for delivering RNA-
products and other drugs. However, there is no platform to manufacture pharmaceutical …
products and other drugs. However, there is no platform to manufacture pharmaceutical …
Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
L Wu, X Li, X Qian, S Wang, J Liu, J Yan - Vaccines, 2024 - mdpi.com
In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …
Dental healthcare amid the covid-19 pandemic
RT Butt, OS Janjua, SM Qureshi, MS Shaikh… - International journal of …, 2021 - mdpi.com
The hustle and bustle of the planet Earth have come to a halt thanks to the novel
coronavirus. The virus has affected approximately 219 million people globally; taken the …
coronavirus. The virus has affected approximately 219 million people globally; taken the …
Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices
Advancements in nanotechnology have resulted in the introduction of several nonviral
delivery vectors for the nontoxic, efficient delivery of encapsulated mRNA-based vaccines …
delivery vectors for the nontoxic, efficient delivery of encapsulated mRNA-based vaccines …
Synthesis of cell penetrating peptide sterol coupler and its liposome study on S-mRNA
Y Li, W Ma, W Su, Z Yan, L Jia, J Deng, A Zhu… - European Journal of …, 2023 - Elsevier
In order to overcome the current LNP-mRNA delivery system's weakness of poor stability
and rapid degradation by nuclease, a novel chol-CGYKK molecule and then the new …
and rapid degradation by nuclease, a novel chol-CGYKK molecule and then the new …
An outline of contributing vaccine technologies for SARS CoV2 advancing in clinical and preclinical phase-trials
SS Naz, I Munir - Recent patents on biotechnology, 2022 - ingentaconnect.com
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV2) is an RNA
virus involving 4 structural and 16 non-structural proteins, and exhibiting high transmission …
virus involving 4 structural and 16 non-structural proteins, and exhibiting high transmission …
Social Perspectives of COVID-19 Pandemic in Bangladesh: A Review.
The natural spread of various harmful organisms into the environment has resulted in a wide
range of diseases worldwide, including in Bangladesh. In December 2019, the world was …
range of diseases worldwide, including in Bangladesh. In December 2019, the world was …
Lipid Nanoparticle (LNP) Delivery Vector-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
L Wu, X Li, X Qian, S Wang, J Liu, J Yan - 2023 - preprints.org
Lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy in
recent years. The strategy of targeting immune cells in cancer therapy has become a …
recent years. The strategy of targeting immune cells in cancer therapy has become a …